Top 50 Medical Device Startup Investors in Oceania in July 2025

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.

Investing in great people solving hard problems to create a better future.

Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.

GD1 is a Venture Capital firm that invests with high conviction in exciting technology companies originating from New Zealand. Our team is passionate about creating and growing global businesses, and our goal is to transform NZ made into the next generation of globally disruptive tech solutions.

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Auckland University's commercialisation arm

Investing in innovation for a healthy childhood Investing in innovation for a healthy childhood About Cure Kids Ventures Cure Kids Ventures is a seed and early stage investment fund that invests in the commercialisation of innovations in products and services with a potential to

The New Zealand Growth Capital Partners (formerly New Zealand Venture Investment Fund) was established to support early-stage technology companies and to stimulate private investment into this space.

Super-seeded by new entry: Flying Kiwi Angels

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Flying Kiwi Angels ? Helping Kiwi Startups

Punakaiki Fund Limited makes long-term investments into high-growth, revenue-generating New Zealand companies. The company holds 20 investments, $32.3 million in assets, and is raising money in December 2017 for further investment.

Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.

Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.

GD1 is a Venture Capital firm that invests with high conviction in exciting technology companies originating from New Zealand. Our team is passionate about creating and growing global businesses, and our goal is to transform NZ made into the next generation of globally disruptive tech solutions.

Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.

K1W1 provides startups and businesses in New Zealand with early and later-stage venture investments.

Your guide to finding and using government services.

South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.

Skip Capital is a private investment fund investing in technology and infrastructure

National Vision is the second largest and one of the fastest growing optical retail companies in the U.S., helping people to see their best to live their best. Learn more about National Vision Inc. and how to join our team.

Booster is an investment manager, superannuation and default KiwiSaver scheme provider. We offer ethical, New Zealand and specialist investment options.

Co:Act is an investment partnership of experienced venture investors with a network of founders.

Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!

We're an early-stage venture capital firm investing in technology companies at the Seed and Series A stage.

LCO Capital offer value-add financial and intellectual capital to underperforming business lines, using an LCO℠ business model.

At UniServices, we partner with the University of Auckland to transform ideas into real-world solutions that impact globally.

Microsoft for Startups is a global program designed to help startups scale with free access to Azure cloud and a streamlined path into selling alongside Microsoft and our vast partner ecosystem.

CP Ventures is a VC fund that invests internationally in early stage, highly scalable, breakthrough technology companies driven by the 4IR

The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Playford Capital is a venture capital arm of South Australian Government Financing Authority specializing in investments in start-ups, early venture, mid venture, late venture stages, and growth capital.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Archangel is an early stage venture capital fund based in Australia. We work with great founders and investors to build game changing companies together.

Avicella Capital is to identify and finance commercial ventures that ethical and creative entrepreneurs have created to enhance patient outcomes and raise the standard of healthcare.

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Terra Rossa Capital Pty Ltd operates as a venture capital fund. The Company invests in life science companies. Terra Rossa Capital serves clients in Australia.

Sirius Capital is a venture capital firm in China that invests in technology companies.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Anova Capital focus on investment in education, big health and new consumption.

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.